Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet inhibition and patient outcomes (PLATO) trial

Background—Reduced renal function is associated with a poorer prognosis and increased bleeding risk in patients with acute coronary syndromes and may therefore alter the risk-benefit ratio with antiplatelet therapies. In the Platelet Inhibition and Patient Outcomes (PLATO) trial, ticagrelor compared...

Full description

Saved in:
Bibliographic Details
Main Authors: James, Stefan (Author) , Budaj, Andrzej (Author) , Aylward, Philip (Author) , Buck, Kristen K. (Author) , Cannon, Christopher P. (Author) , Cornel, Jan H. (Author) , Harrington, Robert A. (Author) , Horrow, Jay (Author) , Katus, Hugo (Author) , Keltai, Matyas (Author) , Lewis, Basil S. (Author) , Parikh, Keyur (Author) , Storey, Robert F. (Author) , Szummer, Karolina (Author) , Wojdyla, Daniel (Author) , Wallentin, Lars (Author)
Format: Article (Journal)
Language:English
Published: [September 14, 2010]
In: Circulation
Year: 2010, Volume: 122, Issue: 11, Pages: 1056-1067
ISSN:1524-4539
DOI:10.1161/CIRCULATIONAHA.109.933796
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1161/CIRCULATIONAHA.109.933796
Verlag, lizenzpflichtig, Volltext: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.109.933796
Get full text
Author Notes:Stefan James, Andrzej Budaj, Philip Aylward, Kristen K. Buck, Christopher P. Cannon, Jan H. Cornel, Robert A. Harrington, Jay Horrow, Hugo Katus, Matyas Keltai, Basil S. Lewis, Keyur Parikh, Robert F. Storey, Karolina Szummer, Daniel Wojdyla, and Lars Wallentin

MARC

LEADER 00000caa a2200000 c 4500
001 1852708506
003 DE-627
005 20240311131109.0
007 cr uuu---uuuuu
008 230714s2010 xx |||||o 00| ||eng c
024 7 |a 10.1161/CIRCULATIONAHA.109.933796  |2 doi 
035 |a (DE-627)1852708506 
035 |a (DE-599)KXP1852708506 
035 |a (OCoLC)1425875940 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a James, Stefan  |e VerfasserIn  |0 (DE-588)1261759451  |0 (DE-627)180903552X  |4 aut 
245 1 0 |a Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function  |b results from the Platelet inhibition and patient outcomes (PLATO) trial  |c Stefan James, Andrzej Budaj, Philip Aylward, Kristen K. Buck, Christopher P. Cannon, Jan H. Cornel, Robert A. Harrington, Jay Horrow, Hugo Katus, Matyas Keltai, Basil S. Lewis, Keyur Parikh, Robert F. Storey, Karolina Szummer, Daniel Wojdyla, and Lars Wallentin 
264 1 |c [September 14, 2010] 
300 |b Diagramme 
300 |a 12 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Originally published 30 Aug 2010 
500 |a Gesehen am 14.07.2023 
520 |a Background—Reduced renal function is associated with a poorer prognosis and increased bleeding risk in patients with acute coronary syndromes and may therefore alter the risk-benefit ratio with antiplatelet therapies. In the Platelet Inhibition and Patient Outcomes (PLATO) trial, ticagrelor compared with clopidogrel reduced the primary composite end point of cardiovascular death, myocardial infarction, and stroke at 12 months but with similar major bleeding rates. - - Methods and Results—Central laboratory serum creatinine levels were available in 15 202 (81.9%) acute coronary syndrome patients at baseline, and creatinine clearance, estimated by the Cockcroft Gault equation, was calculated. In patients with chronic kidney disease (creatinine clearance <60 mL/min; n=3237), ticagrelor versus clopidogrel significantly reduced the primary end point to 17.3% from 22.0% (hazard ratio [HR], 0.77; 95% confidence interval [CI], 0.65 to 0.90) with an absolute risk reduction greater than that of patients with normal renal function (n=11 965): 7.9% versus 8.9% (HR, 0.90; 95% CI, 0.79 to 1.02). In patients with chronic kidney disease, ticagrelor reduced total mortality (10.0% versus 14.0%; HR, 0.72; 95% CI, 0.58 to 0.89). Major bleeding rates, fatal bleedings, and non-coronary bypass-related major bleedings were not significantly different between the 2 randomized groups (15.1% versus 14.3%; HR, 1.07; 95% CI, 0.88 to 1.30; 0.34% versus 0.77%; HR, 0.48; 95% CI, 0.15 to 1.54; and 8.5% versus 7.3%; HR, 1.28; 95% CI, 0.97 to 1.68). The interactions between creatinine clearance and randomized treatment on any of the outcome variables were nonsignificant. - - Conclusions—In acute coronary syndrome patients with chronic kidney disease, ticagrelor compared with clopidogrel significantly reduces ischemic end points and mortality without a significant increase in major bleeding but with numerically more non-procedure-related bleeding. - - Clinical Trial Registration—URL:http://www.clinicatrials.gov. Unique identifier: NCT00391872. 
650 4 |a acute coronary syndrome 
650 4 |a bleeding 
650 4 |a clopidogrel 
650 4 |a mortality 
650 4 |a myocardial infarction 
650 4 |a renal function 
700 1 |a Budaj, Andrzej  |e VerfasserIn  |4 aut 
700 1 |a Aylward, Philip  |e VerfasserIn  |4 aut 
700 1 |a Buck, Kristen K.  |e VerfasserIn  |4 aut 
700 1 |a Cannon, Christopher P.  |e VerfasserIn  |4 aut 
700 1 |a Cornel, Jan H.  |e VerfasserIn  |4 aut 
700 1 |a Harrington, Robert A.  |e VerfasserIn  |4 aut 
700 1 |a Horrow, Jay  |e VerfasserIn  |4 aut 
700 1 |a Katus, Hugo  |d 1951-  |e VerfasserIn  |0 (DE-588)108916618  |0 (DE-627)577155040  |0 (DE-576)289625076  |4 aut 
700 1 |a Keltai, Matyas  |e VerfasserIn  |4 aut 
700 1 |a Lewis, Basil S.  |e VerfasserIn  |4 aut 
700 1 |a Parikh, Keyur  |e VerfasserIn  |4 aut 
700 1 |a Storey, Robert F.  |e VerfasserIn  |4 aut 
700 1 |a Szummer, Karolina  |e VerfasserIn  |4 aut 
700 1 |a Wojdyla, Daniel  |e VerfasserIn  |4 aut 
700 1 |a Wallentin, Lars  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t Circulation  |d Philadelphia, Pa. : Lippincott, Williams & Wilkins, 1950  |g 122(2010), 11 vom: Sept., Seite 1056-1067  |h Online-Ressource  |w (DE-627)265784670  |w (DE-600)1466401-X  |w (DE-576)074891189  |x 1524-4539  |7 nnas  |a Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function results from the Platelet inhibition and patient outcomes (PLATO) trial 
773 1 8 |g volume:122  |g year:2010  |g number:11  |g month:09  |g pages:1056-1067  |g extent:12  |a Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function results from the Platelet inhibition and patient outcomes (PLATO) trial 
856 4 0 |u https://doi.org/10.1161/CIRCULATIONAHA.109.933796  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.109.933796  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20230714 
993 |a Article 
994 |a 2010 
998 |g 108916618  |a Katus, Hugo  |m 108916618:Katus, Hugo  |d 910000  |d 910100  |e 910000PK108916618  |e 910100PK108916618  |k 0/910000/  |k 1/910000/910100/  |p 9 
999 |a KXP-PPN1852708506  |e 4353953680 
BIB |a Y 
SER |a newspaper 
JSO |a {"recId":"1852708506","person":[{"given":"Stefan","display":"James, Stefan","role":"aut","family":"James"},{"family":"Budaj","role":"aut","display":"Budaj, Andrzej","given":"Andrzej"},{"display":"Aylward, Philip","given":"Philip","family":"Aylward","role":"aut"},{"role":"aut","family":"Buck","display":"Buck, Kristen K.","given":"Kristen K."},{"role":"aut","family":"Cannon","given":"Christopher P.","display":"Cannon, Christopher P."},{"given":"Jan H.","display":"Cornel, Jan H.","role":"aut","family":"Cornel"},{"display":"Harrington, Robert A.","given":"Robert A.","role":"aut","family":"Harrington"},{"role":"aut","family":"Horrow","display":"Horrow, Jay","given":"Jay"},{"display":"Katus, Hugo","given":"Hugo","family":"Katus","role":"aut"},{"role":"aut","family":"Keltai","given":"Matyas","display":"Keltai, Matyas"},{"display":"Lewis, Basil S.","given":"Basil S.","role":"aut","family":"Lewis"},{"role":"aut","family":"Parikh","display":"Parikh, Keyur","given":"Keyur"},{"display":"Storey, Robert F.","given":"Robert F.","role":"aut","family":"Storey"},{"family":"Szummer","role":"aut","given":"Karolina","display":"Szummer, Karolina"},{"family":"Wojdyla","role":"aut","display":"Wojdyla, Daniel","given":"Daniel"},{"given":"Lars","display":"Wallentin, Lars","role":"aut","family":"Wallentin"}],"note":["Originally published 30 Aug 2010","Gesehen am 14.07.2023"],"language":["eng"],"name":{"displayForm":["Stefan James, Andrzej Budaj, Philip Aylward, Kristen K. Buck, Christopher P. Cannon, Jan H. Cornel, Robert A. Harrington, Jay Horrow, Hugo Katus, Matyas Keltai, Basil S. Lewis, Keyur Parikh, Robert F. Storey, Karolina Szummer, Daniel Wojdyla, and Lars Wallentin"]},"relHost":[{"pubHistory":["1.1950 -"],"note":["Gesehen am 10.10.2025"],"language":["eng"],"part":{"text":"122(2010), 11 vom: Sept., Seite 1056-1067","issue":"11","extent":"12","pages":"1056-1067","volume":"122","year":"2010"},"corporate":[{"display":"American Heart Association","role":"isb"}],"disp":"Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function results from the Platelet inhibition and patient outcomes (PLATO) trialCirculation","type":{"bibl":"newspaper","media":"Online-Ressource"},"recId":"265784670","origin":[{"dateIssuedKey":"1950","publisherPlace":"Philadelphia, Pa. ; [Erscheinungsort nicht ermittelbar]","publisher":"Lippincott, Williams & Wilkins ; Ovid","dateIssuedDisp":"1950-"}],"title":[{"title":"Circulation","subtitle":"an official journal of the American Heart Association","title_sort":"Circulation"}],"physDesc":[{"extent":"Online-Ressource"}],"id":{"zdb":["1466401-X"],"issn":["1524-4539"],"eki":["265784670"]}}],"origin":[{"dateIssuedDisp":"[September 14, 2010]","dateIssuedKey":"2010"}],"title":[{"subtitle":"results from the Platelet inhibition and patient outcomes (PLATO) trial","title":"Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function","title_sort":"Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function"}],"type":{"bibl":"article-newspaper","media":"Online-Ressource"},"id":{"doi":["10.1161/CIRCULATIONAHA.109.933796"],"eki":["1852708506"]},"physDesc":[{"noteIll":"Diagramme","extent":"12 S."}]} 
SRT |a JAMESSTEFATICAGRELOR1420